$MCRB
Seres Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021018 Filed on November 02, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $975.0K $3.444M
YoY Change -86.5% -97.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $22.40M $18.38M
YoY Change 9.26% -6.03%
% of Gross Profit
Research & Development $46.22M $43.12M
YoY Change 25.76% 8.11%
% of Gross Profit
Depreciation & Amortization $1.627M $1.747M
YoY Change 4.83% 17.01%
% of Gross Profit
Operating Expenses $69.28M $62.55M
YoY Change 22.29% 7.26%
Operating Profit -$59.11M
YoY Change -186.4%
Interest Expense -$466.0K -$862.0K
YoY Change 84.19% 459.74%
% of Operating Profit
Other Income/Expense, Net -$23.00K -$895.0K
YoY Change -92.72% 373.54%
Pretax Income -$68.80M -$60.00M
YoY Change 37.59% -187.96%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$68.80M -$60.00M
YoY Change 37.59% -187.96%
Net Earnings / Revenue -7056.0% -1742.22%
Basic Earnings Per Share -$0.49
Diluted Earnings Per Share -$0.55 -$0.49
COMMON SHARES
Basic Shares Outstanding 124.6M 124.1M
Diluted Shares Outstanding 122.5M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $181.3M $233.0M
YoY Change -37.62% -32.93%
Cash & Equivalents $163.0M $205.4M
Short-Term Investments $18.31M $27.61M
Other Short-Term Assets $13.42M $14.51M
YoY Change 3.88% 42.62%
Inventory $0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $194.8M $247.5M
YoY Change -35.85% -31.02%
LONG-TERM ASSETS
Property, Plant & Equipment $22.99M $19.48M
YoY Change 28.14% 12.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $10.47M $11.54M
YoY Change 101.68% 1819.8%
Total Long-Term Assets $154.0M $64.36M
YoY Change 200.64% 71.7%
TOTAL ASSETS
Total Short-Term Assets $194.8M $247.5M
Total Long-Term Assets $154.0M $64.36M
Total Assets $348.8M $311.9M
YoY Change -1.71% -21.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.44M $10.45M
YoY Change 26.97% 21.18%
Accrued Expenses $18.31M $18.11M
YoY Change 15.7% 38.22%
Deferred Revenue
YoY Change
Short-Term Debt $456.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $85.60M $81.82M
YoY Change 4.06% -13.5%
LONG-TERM LIABILITIES
Long-Term Debt $50.59M $50.86M
YoY Change 105.3% 215.55%
Other Long-Term Liabilities $1.442M $961.0K
YoY Change -87.46% -88.28%
Total Long-Term Liabilities $1.442M $961.0K
YoY Change -87.46% -88.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $85.60M $81.82M
Total Long-Term Liabilities $1.442M $961.0K
Total Liabilities $338.0M $244.3M
YoY Change 51.33% 10.76%
SHAREHOLDERS EQUITY
Retained Earnings -$864.5M -$795.7M
YoY Change 40.72% 41.0%
Common Stock $875.3M $863.4M
YoY Change 17.35% 16.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.78M $67.59M
YoY Change
Total Liabilities & Shareholders Equity $348.8M $311.9M
YoY Change -1.71% -21.3%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$68.80M -$60.00M
YoY Change 37.59% -187.96%
Depreciation, Depletion And Amortization $1.627M $1.747M
YoY Change 4.83% 17.01%
Cash From Operating Activities -$52.89M -$59.58M
YoY Change 1.99% -146.64%
INVESTING ACTIVITIES
Capital Expenditures $3.461M -$1.247M
YoY Change -319.33% -69.53%
Acquisitions
YoY Change
Other Investing Activities $9.387M $41.38M
YoY Change -36.42% 41.69%
Cash From Investing Activities $5.926M $40.13M
YoY Change -55.06% 59.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.597M 98.03M
YoY Change -689.36% 15996.39%
NET CHANGE
Cash From Operating Activities -52.89M -59.58M
Cash From Investing Activities 5.926M 40.13M
Cash From Financing Activities 4.597M 98.03M
Net Change In Cash -42.37M 78.58M
YoY Change 7.38% -48.8%
FREE CASH FLOW
Cash From Operating Activities -$52.89M -$59.58M
Capital Expenditures $3.461M -$1.247M
Free Cash Flow -$56.35M -$58.33M
YoY Change 12.07% -144.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
816000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
58000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5002000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4395000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
3558000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
2292000
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4326290
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Sidney Street - 4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1131000
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
827000
dei City Area Code
CityAreaCode
617
mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
dei Local Phone Number
LocalPhoneNumber
945-9626
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
495000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11538000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5189000
dei Trading Symbol
TradingSymbol
MCRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 us-gaap Assets
Assets
311868000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-676000
CY2021Q4 us-gaap Assets
Assets
354859000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10449000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13735000
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37465
dei Entity Registrant Name
EntityRegistrantName
Seres Therapeutics, Inc.
CY2022Q3 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59169000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
45094000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7333000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6610000
dei Amendment Flag
AmendmentFlag
false
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
CY2021Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#LicenseAndServiceMember
dei Entity Central Index Key
EntityCentralIndexKey
0001609809
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124591741
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205398000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180002000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
27605000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
110704000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14510000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12922000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
247513000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
303628000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19484000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17938000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23747000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18208000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1092000
CY2022Q3 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
4868000
CY2021Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
16819000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
81819000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
82258000
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
50857000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
24643000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17850000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17958000
CY2022Q3 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
92796000
CY2021Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
86998000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
961000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11495000
CY2022Q3 us-gaap Liabilities
Liabilities
244283000
CY2021Q4 us-gaap Liabilities
Liabilities
223352000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1061000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
311868000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
354859000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
316000
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
34112000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
21098000
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
4962000
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
0
CY2022Q3 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
0
CY2021Q4 us-gaap Due To Related Parties Noncurrent
DueToRelatedPartiesNoncurrent
10585000
CY2021Q3 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
-1127000
mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
346000
mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
-1127000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124410917
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124410917
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91889418
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91889418
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
124000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
92000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
863294000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
745829000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-118000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-795715000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-614354000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67585000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3444000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
126725000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6153000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
136636000
CY2022Q3 mcrb Revenue From Grant
RevenueFromGrant
0
CY2021Q3 mcrb Revenue From Grant
RevenueFromGrant
0
mcrb Revenue From Grant
RevenueFromGrant
0
mcrb Revenue From Grant
RevenueFromGrant
1070000
CY2022Q3 us-gaap Revenues
Revenues
3444000
CY2021Q3 us-gaap Revenues
Revenues
126725000
us-gaap Revenues
Revenues
6153000
us-gaap Revenues
Revenues
137706000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43116000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39882000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
126700000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
105139000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18384000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19563000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57290000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48755000
CY2022Q3 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
1051000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
62551000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
58318000
us-gaap Operating Expenses
OperatingExpenses
184336000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4370000
us-gaap Operating Expenses
OperatingExpenses
152767000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4839000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-59107000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
68407000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
us-gaap Operating Income Loss
OperatingIncomeLoss
-178183000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15061000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
865000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
590000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1644000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2385000
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1727000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
744000
us-gaap Interest Expense Debt
InterestExpenseDebt
4140000
us-gaap Interest Expense Debt
InterestExpenseDebt
2172000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-682000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-729000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-895000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-189000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3178000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-516000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60002000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122527275
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91757614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102380700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91649035
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122527275
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94953117
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102380700
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91649035
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
140000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-56000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
138000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-58000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
892000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5079000
mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
2429000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2097000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
553000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59864000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
68217000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-181419000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15519000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
174750000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
372000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
392000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3624000
CY2021Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
32000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35465000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
143705000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
586000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5078000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
27000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-48330000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
101066000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
435000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5846000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-1000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
175738000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-155000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-56624000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
80956000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
130000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6748000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-41000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-64735000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23058000
CY2022Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3279000
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96721000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
429000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
877000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6364000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
138000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60002000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67585000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
us-gaap Share Based Compensation
ShareBasedCompensation
18191000
us-gaap Share Based Compensation
ShareBasedCompensation
14548000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
368000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-346000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3279000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
1127000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1769000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
76502000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50902000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-12899000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-5001000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8137000
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-6153000
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
2863000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3250000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4781000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3520000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2185000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
2933000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
42960000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-175924000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
58551000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6360000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7988000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
36138000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
66342000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
119000000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
125982000
mcrb Payments For Restricted Investments
PaymentsForRestrictedInvestments
0
mcrb Payments For Restricted Investments
PaymentsForRestrictedInvestments
750000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
27606000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1907000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
125005000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1958000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
25583000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
111411000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
116049000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
213583000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
227460000
us-gaap Interest Paid Net
InterestPaidNet
3282000
us-gaap Interest Paid Net
InterestPaidNet
1836000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
213583000
mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
33809000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31746030
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
3.15
CY2022Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
96721000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-795715000
CY2022Q3 mcrb Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
233003000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In the condensed consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8000000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
205398000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180002000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
64754000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
58206000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2022Q3 mcrb Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2021Q3 mcrb Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q3 mcrb Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2021Q3 mcrb Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
27719000
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
114000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
27605000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
111258000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
59000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
111199000
CY2022Q3 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2021Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
27719000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
27605000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
110762000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
110704000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
0
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
0
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
496000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
495000
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
27719000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
27605000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
111258000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
111199000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45270000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40268000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9216000
CY2022Q3 mcrb Accrued Liability Related To2021 License Agreement Current
AccruedLiabilityRelatedTo2021LicenseAgreementCurrent
34112000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19484000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17938000
CY2021Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
1389000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1747000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5002000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1493000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4395000
CY2022Q3 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
10147000
CY2021Q4 mcrb Accrued Development And Clinical Manufacturing Costs Current
AccruedDevelopmentAndClinicalManufacturingCostsCurrent
11147000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10781000
CY2021Q4 mcrb Accrued Liability Related To2021 License Agreement Current
AccruedLiabilityRelatedTo2021LicenseAgreementCurrent
21098000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4129000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3633000
CY2022Q3 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59169000
CY2021Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
45094000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain leases include one or more options to renew, exercisable at the Company’s sole discretion, with renewal terms that can extend the lease from one year to five years.
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2021Q3 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
770000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5900000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2327000
CY2021Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
3573000
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2021Q3 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
767000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2662000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1273000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1135000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23747000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18208000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7333000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6610000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17850000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17958000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25183000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
24568000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1785000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1278000
us-gaap Operating Lease Cost
OperatingLeaseCost
5405000
us-gaap Operating Lease Cost
OperatingLeaseCost
3595000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
326000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
363000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1035000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
758000
us-gaap Variable Lease Cost
VariableLeaseCost
3437000
us-gaap Variable Lease Cost
VariableLeaseCost
2182000
CY2022Q3 mcrb Sublease Income1
SubleaseIncome1
0
CY2021Q3 mcrb Sublease Income1
SubleaseIncome1
-437000
mcrb Sublease Income1
SubleaseIncome1
0
mcrb Sublease Income1
SubleaseIncome1
-1361000
CY2022Q3 us-gaap Lease Cost
LeaseCost
3246000
CY2021Q3 us-gaap Lease Cost
LeaseCost
1962000
us-gaap Lease Cost
LeaseCost
9877000
us-gaap Lease Cost
LeaseCost
5508000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1937000
us-gaap Operating Lease Payments
OperatingLeasePayments
5382000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
1625000
us-gaap Operating Lease Payments
OperatingLeasePayments
3488000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
282163
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.89
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2386000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8446000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3387000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3277000
CY2022Q3 mcrb Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16199000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33695000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8512000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25183000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M20D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M20D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
50000000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
50000000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
3.15
CY2022Q2 mcrb Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
96721000
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27525000
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8738243
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11517189
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.10
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28006768000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4391197
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
717514
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.48
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60002000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14908709
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.05
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M15D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16414140000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7057137
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
10814736000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.07
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.53
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.89
CY2021 mcrb Number Of Employees Granted
NumberOfEmployeesGranted
2
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6364000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5846000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18191000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14548000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-60002000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
68218000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-181361000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15577000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122527275
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91757614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102380700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91649035
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
68218000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-60002000
us-gaap Net Income Loss
NetIncomeLoss
-181361000
us-gaap Net Income Loss
NetIncomeLoss
-15577000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-60002000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
68218000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-181361000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15577000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
122527275
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91757614
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102380700
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91649035
CY2021Q3 mcrb Incremental Common Shares Attributable To Dilutive Effect Of Stock Options To Purchase Common Stock
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsToPurchaseCommonStock
3186762
CY2021Q3 mcrb Incremental Common Shares Attributable To Dilutive Effect Of Unvested Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfUnvestedRestrictedStockUnits
8741
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122527275
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94953117
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102380700
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91649035
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.77
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2016Q1 mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2022Q3 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
3444000
CY2021Q3 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
-4618000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
6153000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
4028000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8738243
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
3.15
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27525000

Files In Submission

Name View Source Status
0000950170-22-021018-index-headers.html Edgar Link pending
0000950170-22-021018-index.html Edgar Link pending
0000950170-22-021018.txt Edgar Link pending
0000950170-22-021018-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img49713950_0.jpg Edgar Link pending
img49713950_1.jpg Edgar Link pending
img49713950_2.jpg Edgar Link pending
img49713950_3.jpg Edgar Link pending
mcrb-20220930.htm Edgar Link pending
mcrb-20220930.xsd Edgar Link pending
mcrb-ex10_1.htm Edgar Link pending
mcrb-ex31_1.htm Edgar Link pending
mcrb-ex31_2.htm Edgar Link pending
mcrb-ex32_1.htm Edgar Link pending
mcrb-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
mcrb-20220930_pre.xml Edgar Link unprocessable
mcrb-20220930_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mcrb-20220930_def.xml Edgar Link unprocessable
mcrb-20220930_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
mcrb-20220930_lab.xml Edgar Link unprocessable